Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 116Stomach Neoplasms 20HER2-positive Breast Cancer 14Neoplasm Metastasis 13Neoplasms 12Colorectal Neoplasms 11Esophageal Neoplasms 9Triple Negative Breast Neoplasms 5Lung Neoplasms 5Endometrial Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Meningeal Neoplasms 4Inflammatory Breast Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Hematologic Neoplasms 3Gallbladder Neoplasms 3Breast Diseases 3Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

Anastrozole 5palbociclib 4abemaciclib 3Trastuzumab 3Fulvestrant 3ribociclib 2pertuzumab 2exemestane 2Tamoxifen 2Letrozole 2Gonadotropin-Releasing Hormone 2AZD9833 2trastuzumab deruxtecan 1taxane 1elacestrant 1dalpiciclib 1STX-478 1RAD1901 1Metformin 1Leflunomide 1Imlunestrant 1Genotype 1Body Height 1Blood Specimen Collection 1Blood Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Diseases × Trastuzumab × 1 year × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

Incepta Pharmaceuticals Ltd

Phase 1 Completed
80 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
44 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡